EyePoint Pharmaceuticals sees increase in Q1 revenue: 3 details

Specialty biopharmaceutical company EyePoint Pharmaceuticals reported $2 million in revenue for the first quarter of 2019, up from $928,000 year over year.

Advertisement

Three details from the financial report:

1. EyePoint’s cash and cash equivalents totaled $43.4 million at the end of the third quarter.

2. Operating expenses for the third quarter increased to $16.7 million from $5.6 million the prior year.

3. The company reported a third-quarter net loss of $19.2 million, or $0.20 per share, compared to a net loss of $7 million, or $0.15 per share, for the prior-year quarter.

More articles on supply chain:
Arkansas ASC pioneers rare, $150K dental robot — 5 details
OrthoIllinois selects HSTpathways software for ASC management
Frost & Sullivan recognizes NextGen Healthcare’s RCM solutions — 3 insights

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Beyond the bottleneck: How health systems are improving access, flow and care continuity

Thursday, July 30
1:00 PM - 2:00 PM CDT

Presenters: Imamu Tomlinson, MD, MBA, VituityWilliam Morice II, MD, PhD, Mayo Clinic LaboratoriesJordan Dale, MD, Houston MethodistAsh Tengshe, City of HopeChris Klay, MHA, MA, PT, FACHE, Hospital Sisters Health System

Advertisement

Next Up in Supply chain

Advertisement

Comments are closed.